7. Eliquis

eliquis
After more than six years on the market and significant investments in DTC advertising, Eliquis shows little sign of slowing down. (Pfizer and Bristol-Myers Squibb)

7. Brand: Eliquis
Company: Pfizer and Bristol-Myers Squibb
What is it: next-gen anticoagulant
2019 spend: $158.5 million
2018 spend: $196.1 million

After more than six years on the market and significant investments in DTC advertising, Eliquis shows little sign of slowing down. The market-leading anticoagulant—ahead of branded competitors Johnson & Johnson’s Xarelto and Boehringer Ingelheim’s Pradaxa, as well as generic warfarin—ran six different TV commercials across two indications last year, where the majority of its ad budget goes.

RELATED: After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO

In commercials for atrial fibrillation treatment, Eliquis touts its better results over warfarin, while in commercials for the treatment of deep vein thrombosis and/or pulmonary embolism, it sticks to simply saying Eliquis is better than the standard treatment.

Sales are way up as well. Bristol-Myers Squibb reported global 2019 Eliquis sales of $7.9 billion, with U.S. sales accounting for $4.76 billion, a 26% increase over 2018's haul.

But generics are knocking at the door, with 25 companies filing for FDA approval for their copycats in 2017. However, Bristol-Myers and Pfizer threw up a patent wall of lawsuits and have gotten key extensions on their patents out as far as 2026, which the drugmakers are arguing is when Eliquis generics should be allowed to enter.

RELATED: Bristol-Myers is counting on DTC to keep driving Eliquis growth

DTC helped get Eliquis where it is, so it’s not likely a strategy Bristol-Myers and Pfizer would abandon. In 2014, when the drug was struggling to rack up sales, a BMS spokesperson told FiercePharma that DTC was working to move the needle and it planned to stay that course and even increase spending behind the initial campaign.

7. Eliquis

Suggested Articles

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.